Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02471391
Recruitment Status : Unknown
Verified June 2015 by Peter MacCallum Cancer Centre, Australia.
Recruitment status was:  Recruiting
First Posted : June 15, 2015
Last Update Posted : August 31, 2015
Sponsor:
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

Tracking Information
First Submitted Date  ICMJE May 12, 2015
First Posted Date  ICMJE June 15, 2015
Last Update Posted Date August 31, 2015
Study Start Date  ICMJE June 2015
Estimated Primary Completion Date June 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 10, 2015)
Complete response measured using IWG at 16 weeks [ Time Frame: Measured at 16 weeks after commencement of treatment. ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 14, 2015)
  • Completing 4, 16, 28, 40 and 56 weeks of treatment [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Toxicities measured using CTCAE version 4 [ Time Frame: Continuously measured while on treatment up to a maximum of 56 weeks ]
  • Overall response (CR + PR) using IWG criteria at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Complete response using IWG criteria at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Minimal residual disease (MRD) at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Progression free survival [ Time Frame: From start of treatment until the date of first documented progression or date of death from any cause, whichever occures first, assessed up to the date when the last patient has their 13 months assessment. ]
  • Overall survival [ Time Frame: From start of treatment until the date of death from any cause assessed up to the date when the last patient has their 13 months assessment. ]
  • Duration of response [ Time Frame: From first disease response date to the date of earliest recurrance or PD, assessed up to the date when the last patient has their 13 months assessment. ]
  • Time to progression [ Time Frame: From start of treatment until the date of first documented progression assessed up to the date when the last patient has their 13 months assessment. ]
Original Secondary Outcome Measures  ICMJE
 (submitted: June 10, 2015)
  • Completing 4, 16, 28, 40 and 56 weeks of treatment [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Toxicities measured using CTCAE version 4 [ Time Frame: Continuosly measured during the treatment period. ]
  • Overall response (CR + PR) using IWG criteria at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Complete response using IWG criteria at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Minimal residual disease (MRD) at 4, 16, 28, 40 and 56 weeks [ Time Frame: Assessed at 4, 16, 28, 40 and 56 weeks ]
  • Progression free survival [ Time Frame: From start of treatment until the date of first documented progression or date of death from any cause, whichever occures first, assessed up to the date when the last patient has their 13 months assessment. ]
  • Overall survival [ Time Frame: From start of treatment until the date of death from any cause assessed up to the date when the last patient has their 13 months assessment. ]
  • Duration of response [ Time Frame: From first disease response date to the date of earliest recurrance or PD, assessed up to the date when the last patient has their 13 months assessment. ]
  • Time to progression [ Time Frame: From start of treatment until the date of first documented progression assessed up to the date when the last patient has their 13 months assessment. ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
Official Title  ICMJE A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)
Brief Summary

This research will test the combination of two new drugs, called ibrutinib and ABT199, taken together in the treatment of Mantle Cell Lymphoma. Other studies have indicated the potential for these drugs to be used in the treatment of participants with Mantle Cell Lymphoma. In this study, the investigators will test the combination of the two drugs together, in order to determine what effects (good and bad) it has on mantle cell lymphoma.

This study has two phases. The first phase is the Primary Evaluation Phase and will closely monitor the effects of ibrutinib and ABT199 for a period of 13 months. Participants who complete 13 months of treatment and continue benefiting from the study treatments will be allowed to continue both drugs until progression or intolerance in the Continuation Phase. The purpose of this phase is to provide patients with continuing access to both ibrutinib and ABT199. Patients will receive routine care from clinician, who will record any sideeffects that may be experienced.

This is one of the first trials in the world to study the combination of ibrutinib and ABT199 together. Therefore the effectiveness of the combination of the study drugs will be assessed, as will how they affect mantle cell lymphoma and how it develops resistance to the treatments. The investigators also do not know whether combining the two drugs together will cause unexpected side effects. Therefore, the study will monitor patients closely and perform scans, blood tests, bone marrow biopsies and other tests at regular intervals.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Mantle Cell Lymphoma
Intervention  ICMJE
  • Drug: ABT-199
  • Drug: Ibrutinib
Study Arms  ICMJE Experimental: Ibrutinib + ABT-199
Interventions:
  • Drug: ABT-199
  • Drug: Ibrutinib
Publications * Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: June 10, 2015)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2018
Estimated Primary Completion Date June 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject must be >/= 18 years of age.
  2. Subject must have a confirmed diagnosis of Mantle Cell Lymphoma (MCL) according to WHO (2008) criteria, and have received at least one prior line of systemic therapy for MCL.
  3. Subject requires treatment in the opinion of the investigator, and has at least one site of radiographically assessable disease not previously irradiated (lymph node with largest diameter >/= 1.5cm, or unequivocal hepatomegaly / splenomegaly)
  4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of </= 2.
  5. Subject must have adequate bone marrow function at Screening as follows:

    • Absolute Neutrophil Count (ANC) >/= 1.0 x 109/L (neutropenia due to marrow infiltration may be supported by growth factors);
    • Platelets >/= 50 x 109/L (entry platelet count must be independent of transfusion within 7 days).
  6. Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening as follows:

    • aPTT and PT not to exceed 1.5 × the upper limit of normal (ULN);
    • Serum creatinine not to exceed 2 x ULN, and a calculated creatinine clearance of at least 50 mL/min using the Cockcroft-Gault equation or a 24-hour urine collection;
    • AST or ALT </= 3.0 × the upper normal limit (ULN) of institution's normal range; Bilirubin </= 1.5 × ULN. Subjects with documented Gilbert's Syndrome may have a bilirubin > 1.5 × ULN.
  7. Female subjects of childbearing potential and non-sterile male subjects (with partners of child bearing potential) must practice at least one of the following methods of birth control with partner(s) from initial study drug administration to 90 days after the last dose of study drug:

    • Total abstinence from sexual intercourse as the preferred life style of the subject; periodic abstinence is not acceptable;
    • Surgically sterile partner(s); acceptable sterility surgeries are: vasectomy, bilateral tubal ligation, bilateral oophorectomy or hysterectomy;
    • Intrauterine device (IUD);
    • Double-barrier method (contraceptive sponge, diaphragm or cervical cap with spermicidal jellies or cream AND a condom);
    • Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration.
  8. Female subjects of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study
  9. Male subjects must agree to refrain from sperm donation, from initial study drug administration until 90 days after the last dose of study drug.
  10. Subject is able to swallow whole tablets.
  11. Subject (or their legally-acceptable representatives) must sign an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study.

Exclusion Criteria:

  1. Subject has undergone an allogeneic stem cell transplant within the last 6 months or currently has active graft-vs-host disease requiring the use of immunosuppressants.
  2. Subject has active and uncontrolled autoimmune cytopenias (for 2 weeks), including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP).
  3. Subject has known central nervous system involvement by MCL.
  4. Subject previously participated in an ibrutinib clinical trial or subject previously received a Bruton's tyrosine kinase (BTK) inhibitor other than ibrutinib
  5. Subject has received the following within 30 days prior to the first dose of study drug:

    •Monoclonal antibody given with anti-neoplastic intent.

  6. Subject has received any of the following within 14 days prior to the first dose of study drug, or has not recovered to less than CTC grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:

    • Any anti-cancer therapy including chemotherapy, or radiotherapy;
    • Investigational therapy, including targeted small molecule agents.
  7. Subject has received the following within 7 days prior to the first dose of study drug:

    •Steroid therapy given with anti-neoplastic intent

  8. Subjects requires ongoing therapy with:

    • Potent CYP3A inhibitors (such as indinavir, ketoconazole, and clarithromycin),
    • Potent CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine or St. John's Wort),
    • Warfarin, or or equivalent vitamin K antagonist (eg, phenprocoumon),
    • Antiretroviral medications.
  9. Subject has consumed the following within 3 days prior to the first dose of study drug.

    • Grapefruit, or
    • Grapefruit products, or
    • Seville oranges (including marmalade containing Seville oranges), or
    • Star fruit
  10. Subject has clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
  11. Subject has a life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.

    •specifically, a subject with history of stroke or intracranial hemorrhage within 6 months prior to enrollment is excluded

  12. Subject has a history of other active malignancies other than MCL within the past 2 years prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the cervix uteri,
    • Adequately treated basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  13. Subject has known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
  14. Received live, attenuated vaccines within 4 weeks of first dose of ibrutinib
  15. Major surgery within 4 weeks of first dose of ibrutinib
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02471391
Other Study ID Numbers  ICMJE 14/148
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Peter MacCallum Cancer Centre, Australia
Study Sponsor  ICMJE Peter MacCallum Cancer Centre, Australia
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Peter MacCallum Cancer Centre, Australia
Verification Date June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP